ProPhase Accounts Payable from 2010 to 2025
| PRPH Stock | USD 0.31 0.08 20.51% |
Accounts Payable | First Reported 1996-12-31 | Previous Quarter 13.6 M | Current Value 15.5 M | Quarterly Volatility 2.7 M |
Check ProPhase Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProPhase Labs' main balance sheet or income statement drivers, such as Interest Expense of 1.5 M, Selling General Administrative of 29.5 M or Total Revenue of 35.5 M, as well as many indicators such as Price To Sales Ratio of 0.96, Dividend Yield of 0.13 or PTB Ratio of 0.86. ProPhase financial statements analysis is a perfect complement when working with ProPhase Labs Valuation or Volatility modules.
ProPhase | Accounts Payable |
Latest ProPhase Labs' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of ProPhase Labs over the last few years. An accounting item on the balance sheet that represents ProPhase Labs obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of ProPhase Labs are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. ProPhase Labs' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProPhase Labs' overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
ProPhase Accounts Payable Regression Statistics
| Arithmetic Mean | 3,546,339 | |
| Geometric Mean | 1,654,199 | |
| Coefficient Of Variation | 112.87 | |
| Mean Deviation | 3,365,924 | |
| Median | 1,296,000 | |
| Standard Deviation | 4,002,785 | |
| Sample Variance | 16T | |
| Range | 11.2M | |
| R-Value | 0.85 | |
| Mean Square Error | 4.9T | |
| R-Squared | 0.71 | |
| Significance | 0.000037 | |
| Slope | 710,801 | |
| Total Sum of Squares | 240.3T |
ProPhase Accounts Payable History
About ProPhase Labs Financial Statements
Investors use fundamental indicators, such as ProPhase Labs' Accounts Payable, to determine how well the company is positioned to perform in the future. Although ProPhase Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 10.8 M | 11.3 M |
Currently Active Assets on Macroaxis
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:Check out the analysis of ProPhase Labs Correlation against competitors. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share | Quarterly Revenue Growth (0.62) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.